EP1324759A4 - Inhibiteurs du nf-g(k)b - Google Patents

Inhibiteurs du nf-g(k)b

Info

Publication number
EP1324759A4
EP1324759A4 EP01979731A EP01979731A EP1324759A4 EP 1324759 A4 EP1324759 A4 EP 1324759A4 EP 01979731 A EP01979731 A EP 01979731A EP 01979731 A EP01979731 A EP 01979731A EP 1324759 A4 EP1324759 A4 EP 1324759A4
Authority
EP
European Patent Office
Prior art keywords
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01979731A
Other languages
German (de)
English (en)
Other versions
EP1324759A2 (fr
Inventor
James F Callahan
Amy K Roshak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1324759A2 publication Critical patent/EP1324759A2/fr
Publication of EP1324759A4 publication Critical patent/EP1324759A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
EP01979731A 2000-10-12 2001-10-12 Inhibiteurs du nf-g(k)b Withdrawn EP1324759A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23975900P 2000-10-12 2000-10-12
US239759P 2000-10-12
PCT/US2001/031866 WO2002030353A2 (fr) 2000-10-12 2001-10-12 INHIBITEURS DU NF-λB

Publications (2)

Publication Number Publication Date
EP1324759A2 EP1324759A2 (fr) 2003-07-09
EP1324759A4 true EP1324759A4 (fr) 2004-05-12

Family

ID=22903601

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01979731A Withdrawn EP1324759A4 (fr) 2000-10-12 2001-10-12 Inhibiteurs du nf-g(k)b

Country Status (4)

Country Link
EP (1) EP1324759A4 (fr)
JP (1) JP2004523476A (fr)
AU (1) AU2002211663A1 (fr)
WO (1) WO2002030353A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
ATE392898T1 (de) 2000-10-26 2008-05-15 Amgen Inc Antiphlogistische mittel
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102617D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
DE60229975D1 (de) * 2001-10-04 2009-01-02 Smithkline Beecham Corp Nf-kb-inhibitoren
EP1444010A2 (fr) * 2001-10-30 2004-08-11 Pharmacia Corporation Derives de carboxamide heteroaromatique destines au traitement des inflammations
AR037641A1 (es) 2001-12-05 2004-11-17 Tularik Inc Moduladores de inflamacion
AU2003249683A1 (en) 2002-06-06 2003-12-22 Smithkline Beecham Corporation Nf-:b inhibitors
JP2005532359A (ja) 2002-06-06 2005-10-27 スミスクライン・ビーチャム・コーポレイション ＮＦ−κＢ阻害剤
EP1556053A4 (fr) 2002-10-31 2006-04-19 Amgen Inc Agents anti-inflammatoires
AU2003300832A1 (en) * 2002-12-06 2004-06-30 Smithkline Beecham Corporation NF-KappaB INHIBITORS
SE0300091D0 (sv) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
KR20060080918A (ko) 2003-08-15 2006-07-11 아스트라제네카 아베 치환된 티오펜 및 이의 용도
MXPA06007054A (es) * 2003-12-19 2007-04-17 Elixir Pharmaceuticals Inc Metodos para tratar una enfermedad.
JP2007517843A (ja) * 2004-01-05 2007-07-05 アストラゼネカ アクチボラグ Ｃｈｋ１阻害剤であるチオフェン誘導体
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
TW200626142A (en) * 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
BRPI0611674A2 (pt) 2005-06-30 2009-04-28 Smithkline Beecham Corp compostos quÍmicos
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
CA2690141A1 (fr) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Inhibiteurs des janus kinases
WO2009132050A2 (fr) 2008-04-21 2009-10-29 Otonomy, Inc. Préparations auriculaires de traitement de maladies et états otiques
WO2010005841A1 (fr) * 2008-07-09 2010-01-14 Merck & Co., Inc. Inhibiteurs des kinases janus
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
WO2012046793A1 (fr) * 2010-10-07 2012-04-12 参天製薬株式会社 Nouvel inhibiteur de jak3 contenant, à titre de principe actif, un dérivé de thiophène portant un groupe uréido et un groupe aminocarbonyle à titre de substituants
EP2520292A1 (fr) 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Utilisation de spirangiens pour le traitement ou la prévention des troubles liés à IL-8 ou IL-6
WO2018005830A1 (fr) 2016-06-29 2018-01-04 Otonomy, Inc. Formulations otiques à base de triglycérides et leurs utilisations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0853083A1 (fr) * 1997-01-06 1998-07-15 Pfizer Inc. Dérivés de pyridylfuran et pyridylthiphène et leur utilisation pharmaceutique
WO2001058890A1 (fr) * 2000-02-12 2001-08-16 Astrazeneca Ab Derives de carboxamides heteroaromatiques et leur utilisation comme inhibiteurs de l'enzyme ikk-2
WO2001098290A2 (fr) * 2000-06-19 2001-12-27 Pharmacia Italia S.P.A. Derives de thiophene actifs en tant qu'inhibiteurs de kinase, leur procede de preparation, et compositions pharmaceutiques les contenant

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468012A (en) * 1973-08-09 1977-03-23 Beecham Group Ltd 2-amino-3-carboxy-thiophene derivatives
JP3236683B2 (ja) * 1992-11-06 2001-12-10 大日本印刷株式会社 熱転写用染料及び熱転写シート
JPH06143838A (ja) * 1992-11-06 1994-05-24 Sankyo Kagaku Kk 感熱転写記録用色素

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0853083A1 (fr) * 1997-01-06 1998-07-15 Pfizer Inc. Dérivés de pyridylfuran et pyridylthiphène et leur utilisation pharmaceutique
WO2001058890A1 (fr) * 2000-02-12 2001-08-16 Astrazeneca Ab Derives de carboxamides heteroaromatiques et leur utilisation comme inhibiteurs de l'enzyme ikk-2
WO2001098290A2 (fr) * 2000-06-19 2001-12-27 Pharmacia Italia S.P.A. Derives de thiophene actifs en tant qu'inhibiteurs de kinase, leur procede de preparation, et compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
WO2002030353A2 (fr) 2002-04-18
WO2002030353A3 (fr) 2002-06-27
EP1324759A2 (fr) 2003-07-09
AU2002211663A1 (en) 2002-04-22
JP2004523476A (ja) 2004-08-05

Similar Documents

Publication Publication Date Title
EP1324759A4 (fr) Inhibiteurs du nf-g(k)b
IL151104A0 (en) Kinase inhibitors
AU2001258771A1 (en) -secretase inhibitors
IL150964A0 (en) Protease inhibitors
AU4217201A (en) Tri-aryl-substituted-ethane pde4 inhibitors
IL156479A0 (en) Substituted-8-arylquinoline phosphodiesterase-4 inhibitors
DE60142731D1 (en) Ation
IL153421A0 (en) Protease inhibitors
IL151087A0 (en) Protease inhibitors
HUP0301964A2 (en) Protease inhibitors
EP1354589A4 (fr) Inhibiteurs d'angiogenese
GB0029733D0 (en) Inhibitors
GB0029730D0 (en) Inhibitors
GB0021193D0 (en) Inhibitors
GB0015996D0 (en) Inhibitors
GB0010763D0 (en) Scale inhibitors
ZA200003399B (en) Inhibitors.
ZA200003398B (en) Inhibitors.
GB0005017D0 (en) Inhibitor
GB0004895D0 (en) Inhibitor
GB0101135D0 (en) Inhibitors
GB0128453D0 (en) Inhibitors
GB0101134D0 (en) Inhibitors
GB0001291D0 (en) Rescue-pump-resuscitator (foot-pump-resuscitator)
GB0020553D0 (en) Concorde-Improvements (Shrapnel-shield)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030411

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040329

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/4409 B

Ipc: 7A 61K 31/4406 B

Ipc: 7A 61K 31/381 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060419